Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...

GE HealthCare has unveiled a new mammography system with artificial intelligence-powered features that it says are aimed at ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...

Roche has struck a $1.5 billion deal to buy Poseida Therapeutics. The takeover will establish off-the-shelf cell therapies, ...

MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...

To recruit volunteers more quickly for clinical trials, a team of National Institutes of Health (NIH) researchers has turned ...

Adcendo is adding $135 million to its arsenal, money that will go toward launching several antibody-drug conjugate (ADC) ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

Roche’s Skyscraper-01 has fallen down. The phase 3 trial found adding the TIGIT candidate tiragolumab to a checkpoint ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...